Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.47 |
| ▸ | NOS1 | P29475 | 5/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278247 | 0.98 | — | — | |
| SCHEMBL1389076 | 0.91 | — | — | |
| SCHEMBL5524836 | 0.79 | — | — | |
| SCHEMBL6903892 | 0.76 | — | — | |
| SCHEMBL4749067 | 0.72 | NOS1 (0.32) | NOS2NOS1NOS3 | |
| SCHEMBL11221727 | 0.70 | NOS3 (0.38) | NOS2NOS1NOS3 | |
| SCHEMBL11877100 | 0.70 | — | — | |
| SCHEMBL1547627 | 0.70 | — | — | |
| SCHEMBL988329 | 0.69 | NOS3 (0.33) | NOS2NOS1NOS3 | |
| SCHEMBL4059958 | 0.68 | NOS1 (0.48) | NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140892-A1 | PHOTOCHROMIC SUBSTIITUTED 2H-NAPHTHO[1,2-B]PYRANS | JAMES ROBINSON LIMITED (GB) | 2001-10-10 | — | — | EP | claimed |
| US-6232312-B1 | ADMINISTERING A COMBINATION OF INDENE AND PYRIMIDO(5,4-D)PYRIMIDINE DERIVATIVES TO TREAT PREPANCREATIC CANCER | CELL PATHWAYS, INC. | 2001-05-15 | — | — | US | claimed |
| WO-2000035902-A1 | PHOTOCHROMIC SUBSTITUTED 2H-NAPHTHO[1,2-b]PYRANS | JAMES ROBINSON LIMITED (GB) | 2000-06-22 | — | — | WO | claimed |
| EP-0338507-A2 | Use of mabuterol and related compounds for intraocular pressure adjustment | Basotherm GmbH (DE) | 1989-10-25 | — | — | EP | claimed |
| US-4055712-A | CONDENSATION OF A TERTIARY AMINE WITH 1,4-DIHALO-2-BUTENE, QUATERNIZATION | KAWANEE INDUSTRIES (US) | 1977-10-25 | — | — | US | claimed |
| US-4036959-A | CATIONIC POLYAMINES | MILLMASTER ONYX CORPORATION (US) | 1977-07-19 | — | — | US | claimed |
| US-20180015090-A1 | COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF | REALINN LIFE SCIENCE LIMITED (TW) | 2018-01-18 | — | — | US | disclosed |
| EP-3250201-A1 | COMPOUNDS FOR ENHANCING PPAR EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF | Realinn Life Science Limited (TW) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016119701-A1 | COMPOUNDS FOR ENHANCING PPARγ EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF | REALINN LIFE SCIENCE LIMITED (TW) | 2016-08-04 | — | — | WO | disclosed |
| EP-1140892-A1 | PHOTOCHROMIC SUBSTIITUTED 2H-NAPHTHO[1,2-B]PYRANS | JAMES ROBINSON LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140892-A1 | PHOTOCHROMIC SUBSTIITUTED 2H-NAPHTHO[1,2-B]PYRANS | JAMES ROBINSON LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| US-6232312-B1 | ADMINISTERING A COMBINATION OF INDENE AND PYRIMIDO(5,4-D)PYRIMIDINE DERIVATIVES TO TREAT PREPANCREATIC CANCER | CELL PATHWAYS, INC. | 2001-05-15 | — | — | US | disclosed |
| WO-2000035902-A1 | PHOTOCHROMIC SUBSTITUTED 2H-NAPHTHO[1,2-b]PYRANS | JAMES ROBINSON LIMITED (GB) | 2000-06-22 | — | — | WO | disclosed |
| EP-0338507-A2 | Use of mabuterol and related compounds for intraocular pressure adjustment | Basotherm GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338507-A2 | Use of mabuterol and related compounds for intraocular pressure adjustment | Basotherm GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
| US-4055712-A | CONDENSATION OF A TERTIARY AMINE WITH 1,4-DIHALO-2-BUTENE, QUATERNIZATION | KAWANEE INDUSTRIES (US) | 1977-10-25 | — | — | US | disclosed |
| US-4036959-A | CATIONIC POLYAMINES | MILLMASTER ONYX CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
| US-4012446-A | 1,4-DIHALO-2-BUTENE | MILLMASTER ONYX CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |
| US-4001432-A | FROM 1,4-DIHALO-2-BUTENE, TERTIARY DIAMINE, AND TERTIARY MONOAMINE | MILLMASTER ONYX CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3931319-A | QUATERNARY AMMONIUM ADDITION POLYMERS, MICROBIOCIDES | MILLMASTER ONYX CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015090-A1 | COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF | PPARA, PPARD, PPARG | NOS2 3718/4885NOS1 3951/4885NOS3 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.